Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 24
2003 26
2004 27
2005 27
2006 19
2007 7
2008 6
2009 7
2010 7
2011 6
2012 8
2013 17
2014 8
2015 14
2016 16
2017 21
2018 14
2019 12
2020 21
2021 22
2022 18
2023 22
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
The Role of Inflammation in Age-Related Macular Degeneration.
Tan W, Zou J, Yoshida S, Jiang B, Zhou Y. Tan W, et al. Among authors: yoshida s. Int J Biol Sci. 2020 Sep 23;16(15):2989-3001. doi: 10.7150/ijbs.49890. eCollection 2020. Int J Biol Sci. 2020. PMID: 33061811 Free PMC article. Review.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Editorial: Non-coding RNAs in ophthalmic diseases.
Zhou Y, Li S, Yoshida S. Zhou Y, et al. Among authors: yoshida s. Front Genet. 2022 Nov 10;13:1055701. doi: 10.3389/fgene.2022.1055701. eCollection 2022. Front Genet. 2022. PMID: 36437936 Free PMC article. No abstract available.
Periostin in Eye Diseases.
Yoshida S, Umeno Y, Haruta M. Yoshida S, et al. Adv Exp Med Biol. 2019;1132:113-124. doi: 10.1007/978-981-13-6657-4_12. Adv Exp Med Biol. 2019. PMID: 31037630 Review.
Periostin in vitreoretinal diseases.
Yoshida S, Nakama T, Ishikawa K, Nakao S, Sonoda KH, Ishibashi T. Yoshida S, et al. Cell Mol Life Sci. 2017 Dec;74(23):4329-4337. doi: 10.1007/s00018-017-2651-5. Epub 2017 Sep 14. Cell Mol Life Sci. 2017. PMID: 28913545 Review.
Role of interferons in diabetic retinopathy.
Li BY, Tan W, Zou JL, He Y, Yoshida S, Jiang B, Zhou YD. Li BY, et al. Among authors: yoshida s. World J Diabetes. 2021 Jul 15;12(7):939-953. doi: 10.4239/wjd.v12.i7.939. World J Diabetes. 2021. PMID: 34326947 Free PMC article. Review.
Chromovitrectomy and vital dyes.
Enaida H, Hisatomi T, Nakao S, Ikeda Y, Yoshida S, Ishibashi T. Enaida H, et al. Among authors: yoshida s. Dev Ophthalmol. 2014;54:120-5. doi: 10.1159/000360457. Epub 2014 Aug 26. Dev Ophthalmol. 2014. PMID: 25196760 Review.
326 results